Summary
This phase III trial (EV-302/KEYNOTE-A39) evaluated the combination of enfortumab vedotin, a targeted antibody–drug conjugate, with pembrolizumab, a PD-1 checkpoint inhibitor, in patients with previously untreated locally advanced or metastatic urothelial carcinoma. The 2.5-year median follow-up data reported here extend the efficacy and safety observations from the initial trial analysis. Although this falls outside Vitagri's core remit of farming systems and nutrient density, the study represents contemporary oncology practice and may be of tangential interest to health-outcomes researchers.
UK applicability
The findings would be relevant to UK oncology practice and NHS commissioning decisions regarding first-line treatment of advanced urothelial carcinoma, though direct applicability depends on UK regulatory approval status and health economic evaluation of the combination therapy.
Key measures
Overall survival, progression-free survival, response rates, safety and tolerability profiles
Outcomes reported
The study reports efficacy and safety outcomes of combined enfortumab vedotin and pembrolizumab in patients with untreated locally advanced or metastatic urothelial carcinoma, with median follow-up of 2.5 years.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.